IRIS UniCatt

De Marinis Grasso, Laura
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.159
EU - Europa 5.787
AS - Asia 5.372
SA - Sud America 1.159
AF - Africa 140
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 5
Totale 19.633
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.946
SG - Singapore 2.301
DE - Germania 2.203
CN - Cina 1.294
BR - Brasile 932
SE - Svezia 821
IT - Italia 614
VN - Vietnam 609
UA - Ucraina 558
FR - Francia 453
GB - Regno Unito 273
IE - Irlanda 227
IN - India 218
BD - Bangladesh 183
FI - Finlandia 181
ID - Indonesia 159
JP - Giappone 139
RU - Federazione Russa 134
HK - Hong Kong 114
CA - Canada 109
AR - Argentina 84
TR - Turchia 65
MX - Messico 56
IQ - Iraq 55
NL - Olanda 50
PL - Polonia 48
BE - Belgio 46
EC - Ecuador 38
AT - Austria 35
ES - Italia 35
PK - Pakistan 32
ZA - Sudafrica 31
MA - Marocco 25
VE - Venezuela 24
SA - Arabia Saudita 23
CL - Cile 22
CO - Colombia 20
UZ - Uzbekistan 20
KR - Corea 18
AE - Emirati Arabi Uniti 16
EG - Egitto 14
PE - Perù 14
KZ - Kazakistan 13
PY - Paraguay 13
RO - Romania 13
AL - Albania 12
CH - Svizzera 12
IR - Iran 12
JO - Giordania 12
MY - Malesia 11
PT - Portogallo 11
SN - Senegal 11
TN - Tunisia 11
AZ - Azerbaigian 10
CZ - Repubblica Ceca 10
CI - Costa d'Avorio 9
CR - Costa Rica 9
JM - Giamaica 9
KE - Kenya 9
LT - Lituania 9
AU - Australia 8
PH - Filippine 8
DZ - Algeria 7
ET - Etiopia 7
IL - Israele 7
LB - Libano 7
MD - Moldavia 7
BO - Bolivia 6
DO - Repubblica Dominicana 6
LK - Sri Lanka 6
NP - Nepal 6
QA - Qatar 6
TT - Trinidad e Tobago 6
UY - Uruguay 6
NO - Norvegia 5
BG - Bulgaria 4
GE - Georgia 4
HN - Honduras 4
HU - Ungheria 4
NG - Nigeria 4
OM - Oman 4
PA - Panama 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AM - Armenia 3
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
DK - Danimarca 3
GT - Guatemala 3
KG - Kirghizistan 3
LV - Lettonia 3
RS - Serbia 3
AO - Angola 2
BS - Bahamas 2
EU - Europa 2
GR - Grecia 2
HR - Croazia 2
KW - Kuwait 2
ME - Montenegro 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
Totale 19.606
Salva come PNG Salva come JPEG
Città #
Singapore 1.216
Chandler 847
Ashburn 749
San Jose 716
Beijing 235
Jacksonville 222
New York 221
Dublin 218
Ho Chi Minh City 216
San Mateo 214
Ann Arbor 206
Los Angeles 173
Nanjing 149
Hanoi 140
Jakarta 138
Rome 133
Lauterbourg 132
Wilmington 126
Hefei 124
Tokyo 112
Boston 109
Hong Kong 100
Nürnberg 98
Munich 94
The Dalles 94
Milan 92
Houston 91
Marseille 90
São Paulo 89
Moscow 88
Chicago 82
Frankfurt am Main 81
Dearborn 79
Dallas 73
Woodbridge 69
Princeton 66
Helsinki 57
Santa Clara 56
Seattle 54
Cattolica 52
Lawrence 52
Redwood City 51
Nanchang 50
Kent 49
Bremen 48
Tukwila 48
St Louis 46
Boardman 45
Brussels 44
Mountain View 43
Zhengzhou 43
Buffalo 41
University Park 40
Montreal 38
Hangzhou 36
Izmir 35
Shanghai 35
Detroit 34
Rio de Janeiro 34
Delhi 33
Da Nang 32
Orem 32
Fairfield 31
Brooklyn 30
Warsaw 30
Denver 29
Norwalk 28
Shenyang 28
Lancaster 27
Paris 27
Turku 27
Fremont 26
London 25
Nuremberg 24
Changsha 23
Atlanta 22
Guangzhou 22
Haiphong 22
Leawood 22
Tianjin 22
Belo Horizonte 21
Kunming 21
Chennai 20
Hebei 20
Baghdad 19
Düsseldorf 19
Redmond 19
Jiaxing 18
Amsterdam 17
Poplar 17
Stockholm 17
Tashkent 17
Toronto 17
Cambridge 16
Mumbai 16
Porto Alegre 16
Bexley 15
Dhaka 15
Johannesburg 15
Las Vegas 15
Totale 9.625
Salva come PNG Salva come JPEG
Nome #
Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries 326
Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review 307
The treatment of neuroendocrine tumors with long-acting somatostatin analogs: A single center experience with lanreotide autogel 297
Growth hormone in inflammatory bowel disease 262
Evaluation of antioxidants systems in pituitary-adrenal axis diseases. 252
Predictors of morbidity and mortality in acromegaly, an Italian survey. 243
Double pituitary adenomas 238
Seminal antioxidant capacity in pre- and postoperative varicocele 236
Coenzyme Q10 evaluation in pituitary-adrenal axis disease: preliminary data. 217
Evaluation of Antioxidant systems (Coenzyme Q10 and total antioxidant capacity) in morbidy obesity before and after biliopancreatic diversion 217
Typical and Atypical Pituitary Adenomas: A Single-Center Analysis of Outcome and Prognosis 212
An Overview of Diagnosis of Primary Autoimmune Hypophysitis in a Single Prospective Monocentric Experience 202
Effects of gherlin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome 200
Relationships between plasma CoQ10 levels and thyroid hormones in chronic obstructive pulmonary disease. 200
Non Alcoholic Fatty Liver Disease is Associated with Increased GHBP and Reduced GH/IGF-I Levels 200
Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study 199
Male fertility and reduction in semen parameters: A single tertiary-care center experience 192
Increased estradiol levels in venous occlusive disorder: a possible functional mechanism of venous leakage. 191
Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels 190
Circulating endothelial cells as marker of endothelial damage in male hypogonadism 189
Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography 187
Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography. 183
Primary hyperparathyroidism. Our experience 180
NOVEL BIOMARKERS OF ANDROGEN DEFICIENCY FROM SEMINAL PLASMA PROFILING USING HIGH-RESOLUTION MASS SPECTROMETRY. 179
[Immunogenetic and functional study of first-degree relatives of patients with type I diabetes mellitus for identifying prediabetic subjects] 175
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: An immunohistochemical study 174
Pancreatic metastases from a bronchopulmonary carcinoid diagnosed by endoscopic ultrasonography-guided fine-needle tissue acquisition 168
Isolated growth hormone deficiency: clinical entity? 167
[Coexistence of hyperthyroidism and thyroid carcinoma. Description of a clinical case] 166
Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study 164
Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly. 163
Effects of ghrelin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome 161
Xanthogranuloma of the sellar region: A rare tumor. Case illustration and literature review 161
Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. 160
Circulating endothelial cells as marker of endothelial damage in male hypogonadism 159
Corticotropin-releasing hormone inhibition of gonadotropin release and the effect of opioid blockade 158
Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients. 158
Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study 158
Influence of diabetes mellitus on vertebral fractures in men with acromegaly 153
Proteomic approach in the identification of fertility pattern in seminal plasma of fertile men 153
Hypotestosteronemia is frequent in ST-elevation myocardial infarction patients and is associated with coronary microvascular obstruction 153
Effects of Testosterone on antioxidant systems in male secondary hypogonadism. 152
Significant GH-deficiency after long-term cure by surgery in adult patients with Cushing s disease 151
Radically resected pituitary adenomas: prognostic role of Ki67 labeling index in monocentric retrospective series and literature review 151
The effect of treatment with growth hormone on fertility outcome in eugonadal women with growth hormone deficiency: report of four cases and review of the literature 149
Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency 147
Naloxone inhibition of postprandial growth hormone releasing hormone-induced growth hormone release in obesity 147
Hypothalamitis: a diagnostic and therapeutic challenge 145
DIAGNOSIS OF ENDOCRINE DISEASE: Primary Empty Sella: a comprehensive review 145
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response 145
Endocrine status in patients with mammary gland diseases: correlation between steroid hormones and sex steroid binding globulin 143
Hormonal and metabolic evaluation in Down's syndrome: preliminary evidence for TSH dysregulation in hyperthyrotropinemic patients 143
Fertility and hypopituitarism 142
GH receptor isoforms and skeletal fragility in acromegaly 141
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. 139
Plasma prolactin response to gonadotropin-releasing hormone during benzodiazepine treatment 135
Increased total antioxidant capacity in seminal plasma of varicocele patients: a multivariate analysis 135
ACTH-dependent Cushing syndrome: The potential benefits of simultaneous bilateral posterior retroperitoneoscopic adrenalectomy 133
Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: preliminary report. 133
Prolactin dynamics in normoprolactinemic primary empty sella: correlation with intracranial pressure 133
Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second Line Therapies: A Longitudinal Study 133
Hypotestosteronemia is frequent in ST-elevation myocardial infarction patients and is associated with coronary microvascular obstruction 130
Endocrine evaluation of patients with benign lumps of the breast 129
Pancreas as an Unusual Metastatic Site of Medullary Thyroid Carcinoma: A Case of Very Long-term Follow-up Under Prolonged Treatment with Somatostatin Analogues 128
Corticotropin-releasing hormone inhibition of gonadotropin secretion during the menstrual cycle 128
Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes 128
The treatment of hyperinsulinemic hypoglycaemia in adults: an update 127
Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors. 127
The changing clinical spectrum of endocrine adverse events in cancer immunotherapy 127
High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas 126
Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA 126
Prevalence of vertebral fractures in men with acromegaly 125
First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome. 124
Genes of the “regulation of lymphocyte activation” pathway may influence immune cells infiltration in growth hormone secreting pituitary tumors 120
SOMATOSTATIN ANALOGUES VS ACTIVE SURVEILLANCE IN SMALL PANCREATIC NEUROENDOCRINE TUMORS 120
Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. 120
Empty sella syndrome: Multiple endocrine disorders. 120
Autoantibody reactivity profile of primary autoimmune hypophysitis patients: preliminary results 120
CD68+ and CD8+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs 119
Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapy 118
Primary empty sella: Why and when to investigate hypothalamic-pituitary function 116
Effects of high-dose octreotide lar on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy 116
Synchronous Bilateral Adrenalectomy in ACTH-dependent Hypercortisolism: Predictors, Biomarkers and Outcomes 116
Reciprocal regulation of microrna-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions 115
Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency 114
Human leucocyte antigens coeliac haplotypes and primary autoimmune hypophysitis in caucasian patients 114
Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors 113
Nonthyroidal illness syndrome and prolonged mechanical ventilation in patients admitted to the ICU. 113
Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. 113
Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: A multicenter study 110
Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients. 110
Acromegaly in the elderly patients 110
The Role of Growth Hormone Receptor Isoforms and Their Effects in Bone Metabolism and Skeletal Fragility 110
Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review 109
Pregnancy in Autoimmune Hypophysitis: Management of a Rare Condition 109
Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin? 108
Understanding the effect of acromegaly on the human skeleton. 108
Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant 108
Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. 106
Endocrine evaluation of patients with benign lumps of the breast 105
Totale 15.477
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.939
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.939
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 0 0 12
2021/20221.163 60 96 20 79 112 45 26 175 50 66 183 251
2022/20232.397 302 346 194 337 172 283 135 183 266 42 77 60
2023/20241.052 61 319 21 43 51 163 37 19 28 34 118 158
2024/20252.512 63 63 170 81 173 85 28 118 412 221 498 600
2025/20267.895 1.046 268 516 943 1.166 393 1.280 408 439 577 620 239
Totale 19.909